ALX Oncology Holdings Inc. (ALXO)
After hours:
| Previous Close | 4.7600 |
| Open | 4.7400 |
| Bid | 4.6900 x 1000 |
| Ask | 4.9400 x 800 |
| Day's Range | 4.6400 - 4.9700 |
| 52 Week Range | 3.9360 - 13.6400 |
| Volume | |
| Avg. Volume | 159,487 |
| Market Cap | 203.701M |
| Beta (5Y Monthly) | 1.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.1300 |
| Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.71 |
GlobeNewswireALX Oncology Realigns Executive Leadership Team
Jason Lettmann appointed as Chief Executive OfficerDr. Jaume Pons transitions to Chief Scientific Officer SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that Jason Lettmann, a member of the Board of Directors, will succeed Jaume Pons, Ph.D. as Chief Executive Officer, effective September 6, 20
- GlobeNewswire
ALX Oncology Announces September Investor Conference Participation
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in two upcoming investor conferences. H.C. Wainwright 25th Annual Global Investment ConferenceFormat: Fireside chat with analyst, Swayampakula Ramakanth Date: Monday, September 11Time: 2:30 PM Eastern TimeLocation: New York,
- GlobeNewswire
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update
Advancing Phase 2/3 ASPEN-06 gastric cancer trial with data update expected in Q423 Terminating azacitidine combination development programs: ASPEN-02 in MDS and ASPEN-05 in AML Continuing focus on combinations with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 immune checkpoint inhibitors SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies t
